Drug intelligence / Profile preview

AMV602

Development stage: Preclinical
Lead developer: AMVAC Chemical
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

AMV602 is an investigational **respiratory syncytial virus vaccine candidate** developed by AmVac for prevention of RSV infection. Public descriptions identify it as a **genome replication-deficient Sendai virus vector vaccine** expressing a **chimeric RSV/SeV fusion protein**, a design intended to induce both humoral and cellular immunity against RSV. Available public evidence supports only a **preclinical** stage program associated with AmVac and related patent filings; no clear later-stage clinical development or approved product identity was found in the sources reviewed.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on AMV602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMV602.

Explore the full profile